Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study
Identifieur interne : 001316 ( PascalFrancis/Checkpoint ); précédent : 001315; suivant : 001317Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study
Auteurs : David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France]Source :
- Movement disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:08-0251871Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destee">Alain Destée</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0251871</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0251871 INIST</idno><idno type="RBID">Pascal:08-0251871</idno><idno type="wicri:Area/PascalFrancis/Corpus">001262</idno><idno type="wicri:Area/PascalFrancis/Curation">001A57</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001316</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destee">Alain Destée</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName><placeName><settlement type="city">Lille</settlement><region type="region" nuts="2">Nord-Pas-de-Calais</region></placeName><orgName type="university" n="3">Université Lille 2</orgName><orgName type="institution" wicri:auto="newGroup">Université Lille Nord de France</orgName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Citalopram</term><term>Comparative study</term><term>Depression</term><term>Desipramine</term><term>Double blind study</term><term>Nervous system diseases</term><term>Norepinephrine</term><term>Parkinson disease</term><term>Placebo</term><term>Serotonin</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Etat dépressif</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Etude comparative</term><term>Désipramine</term><term>Citalopram</term><term>Traitement</term><term>Etude double insu</term><term>Placebo</term><term>Sérotonine</term><term>Noradrénaline</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>23</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study</s1></fA08><fA11 i1="01" i2="1"><s1>DEVOS (David)</s1></fA11><fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1></fA11><fA11 i1="03" i2="1"><s1>POIROT (Isabelle)</s1></fA11><fA11 i1="04" i2="1"><s1>MOREAU (Caroline)</s1></fA11><fA11 i1="05" i2="1"><s1>COTTENCIN (Olivier)</s1></fA11><fA11 i1="06" i2="1"><s1>THOMAS (Pierre)</s1></fA11><fA11 i1="07" i2="1"><s1>DESTEE (Alain)</s1></fA11><fA11 i1="08" i2="1"><s1>BORDET (Regis)</s1></fA11><fA11 i1="09" i2="1"><s1>DEFEBVRE (Luc)</s1></fA11><fA14 i1="01"><s1>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>8 aut.</sZ></fA14><fA20><s1>850-857</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000195888140120</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>39 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0251871</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short-term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short-term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double-blind, randomized, placebo-controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Etat dépressif</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Depression</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Estado depresivo</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Etude comparative</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Comparative study</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Désipramine</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Desipramine</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Desipramina</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Citalopram</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Citalopram</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Citalopram</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Placebo</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Placebo</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Placebo</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Sérotonine</s0><s2>NK</s2><s2>FR</s2><s5>15</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Serotonin</s0><s2>NK</s2><s2>FR</s2><s5>15</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Serotonina</s0><s2>NK</s2><s2>FR</s2><s5>15</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Noradrénaline</s0><s2>NK</s2><s5>16</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Norepinephrine</s0><s2>NK</s2><s5>16</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Noradrenalina</s0><s2>NK</s2><s5>16</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Trouble de l'humeur</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Mood disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Trastorno humor</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Neurotransmetteur</s0><s5>43</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Neurotransmitter</s0><s5>43</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Neurotransmisor</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Catécholamine</s0><s5>44</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Catecholamine</s0><s5>44</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Catecolamina</s0><s5>44</s5></fC07><fN21><s1>162</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>France</li></country><region><li>Nord-Pas-de-Calais</li></region><settlement><li>Lille</li></settlement><orgName><li>Université Lille 2</li><li>Université Lille Nord de France</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></noRegion><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destee">Alain Destée</name><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001316 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001316 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:08-0251871
|texte= Comparison of Desipramine and Citalopram Treatments for Depression in Parkinson's Disease : A Double-Blind, Randomized, Placebo-Controlled Study
}}
| This area was generated with Dilib version V0.6.23. |  |